Shanghai Haohai Biological Technology Co Ltd

Chart & Performance

D1W1MN

P/E

30.97

P/S

4.89

EPS

0.81

Div Yield, %

0.54%

Shrs. gr., 5y

15.87%

Rev. gr., 5y

11.26%

Revenues

2.63b

+25.27%

Net income

416m

+130.58%

CFO

634m

+174.30%

Dividend

Sep 20, 20240.43867 HKD/sh

Earnings

May 29, 2025

Profile

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, the United States, the United Kingdom, and internationally. It offers ophthalmology products comprising intraocular lens, ophthalmic viscoelastic devices, orthokeratology and phakic refractive lenses, eye drops, injectors, scalpels, etc.; orthopedics products, such as sodium hyaluronate injection and medical chitosan; wound repair products, including recombinant human epidermal growth factor for the treatment of burn wound, residual wound, donor site posttraumatic wound, and fresh or old wound of chronic ulcer; anti-adhesion materials comprising medical sodium hyaluronate gel and medical chitosan; and hemostatic materials, such as collagen sponge and porcine fibrin sealants. The company also provides medical aesthetics products comprising Matrifill, a first-generation HA dermal filler, which is a mono-phase sodium hyaluronate gel for injection; Janlane, a second-generation HA dermal filler for dynamic filling function; Hyalumatrix, a third-generation HA dermal filler that offers precise embellishment function; and radio frequency devices and laser equipment. In addition, it is involved in research and development of biological engineering and pharmaceutical products, as well as in the provision of related technology transfer, and consultation services; and investment and trading business. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. Shanghai Haohai Biological Technology Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.

URL

https://www.3healthcare.com/

IPO date

Apr 30, 2015

Employees

2,123

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	2,634,910 25.27%	2,103,438 20.19%	1,750,116 32.14%
Cost of revenue	2,238,353	1,923,543	1,556,401
Unusual Expense (Income)
NOPBT	396,557	179,895	193,715
NOPBT Margin	15.05%	8.55%	11.07%
Operating Taxes	95,991	45,395	35,366
Tax Rate	24.21%	25.23%	18.26%
NOPAT	300,566	134,500	158,349
Net income	416,121 130.58%	180,470 -48.76%	352,234 53.10%
Dividends	(73,611)	(121,891)	(87,911)
Dividend yield	0.55%	1.91%	0.97%
Proceeds from repurchase of equity	(196,295)	(147,672)	(48,860)
BB yield	1.46%	2.31%	0.54%
Debt
Debt current	216,625	34,378	66,018
Long-term debt	245,517	145,139	86,208
Deferred revenue	13,625	5,500	9,402
Other long-term liabilities	5,639	225,853	195,993
Net debt	(2,884,958)	(3,026,889)	(3,373,909)
Cash flow
Cash from operating activities	634,450	231,296	342,286
CAPEX	(267,230)	(317,148)	(272,097)
Cash from investing activities	(376,650)	(681,815)	(148,090)
Cash from financing activities	(257,727)	(288,350)	(231,251)
FCF	112,434	(161,271)	(60,600)
Balance
Cash	2,751,082	2,541,715	2,907,164
Long term investments	596,018	664,691	618,971
Excess cash	3,215,354	3,101,234	3,438,629
Stockholders' equity	3,267,333	2,931,405	2,880,241
Invested Capital	3,229,152	3,268,507	3,473,172
ROIC	9.25%	3.99%	4.67%
ROCE	6.00%	2.83%	2.98%
EV
Common stock shares outstanding	334,261	173,563	176,125
Price	40.30 9.36%	36.85 -28.45%	51.50 12.20%
Market cap	13,470,713 110.62%	6,395,788 -29.49%	9,070,448 11.50%
EV	11,024,429	3,803,693	6,043,364
EBITDA	594,412	384,112	356,552
EV/EBITDA	18.55	9.90	16.95
Interest	7,295	7,603	4,963
Interest/NOPBT	1.84%	4.23%	2.56%